First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis.
Advanced hepatocellular carcinoma
Atezolizumab
Durvalumab
First line
HCC
ICI
Lenvatinib
Sorafenib
TKI
Tremelimumab
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
15
05
2023
revised:
19
07
2023
accepted:
25
07
2023
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
The rapid development of novel therapeutic options for advanced hepatocellular carcinoma (aHCC) has generated some uncertainty about the rational choice of the systemic upfront treatment. So far, a variety of therapeutic strategies have been investigated, including the combination of immunecheckpoint inhibitors and
Identifiants
pubmed: 37560704
doi: 10.1016/j.heliyon.2023.e18696
pii: S2405-8440(23)05904-2
pmc: PMC10407140
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e18696Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Psychon Bull Rev. 2018 Feb;25(1):143-154
pubmed: 26968853
JHEP Rep. 2023 Feb 18;5(5):100702
pubmed: 37025943
Methods Mol Biol. 2022;2401:239-248
pubmed: 34902132
Crit Rev Oncol Hematol. 2018 Nov;131:83-89
pubmed: 30293710
Clin Cancer Res. 2019 Feb 1;25(3):912-920
pubmed: 30274981
PLoS One. 2013 Oct 03;8(10):e76654
pubmed: 24098547
Methods Mol Biol. 2022;2401:1-12
pubmed: 34902118
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Intern Emerg Med. 2017 Feb;12(1):103-111
pubmed: 27913917
Discov Oncol. 2022 Sep 28;13(1):95
pubmed: 36171533
J Clin Oncol. 2013 Oct 1;31(28):3517-24
pubmed: 23980084
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Clin Transl Sci. 2021 Jan;14(1):113-119
pubmed: 33089968
Future Oncol. 2020 Nov;16(32):2587-2589
pubmed: 32772560
Br J Cancer. 2019 Apr;120(9):896-902
pubmed: 30944458
Mol Cancer. 2019 Aug 29;18(1):130
pubmed: 31464625
Front Pharmacol. 2022 Jun 01;13:891008
pubmed: 35721168
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Clin Oncol. 2015 Jan 10;33(2):172-9
pubmed: 25488963
Lancet Oncol. 2022 Aug;23(8):995-1008
pubmed: 35798016
JAMA Oncol. 2020 Dec 1;6(12):e204930
pubmed: 33090186
Braz J Phys Ther. 2019 Jul - Aug;23(4):290-301
pubmed: 30638956
Gan To Kagaku Ryoho. 1996 Aug;23(9):1105-15
pubmed: 8751796
J Gastrointest Surg. 2017 Dec;21(12):2033-2038
pubmed: 28785936
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Evid Based Ment Health. 2014 Nov;17(4):111-6
pubmed: 25288685
ESMO Open. 2022 Jun;7(3):100465
pubmed: 35427835
JAMA Oncol. 2019 Nov 01;5(11):1582-1588
pubmed: 31486832
J Clin Oncol. 2015 Feb 20;33(6):559-66
pubmed: 25547503
Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):333-339
pubmed: 35403533
Expert Opin Investig Drugs. 2022 Apr;31(4):361-369
pubmed: 34798793
High Throughput. 2018 Dec 18;7(4):
pubmed: 30567415
J Clin Oncol. 2021 Nov 20;39(33):3725-3736
pubmed: 34491815
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Future Oncol. 2019 Jun;15(16):1811-1822
pubmed: 30969136
Hepatology. 2016 Sep;64(3):774-84
pubmed: 27082062
J Clin Oncol. 2013 Nov 10;31(32):4067-75
pubmed: 24081937
Lancet Oncol. 2021 Jul;22(7):977-990
pubmed: 34143971
Lancet Oncol. 2022 Jul;23(7):899-909
pubmed: 35690072
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Hepatol. 2015 Oct;63(4):896-904
pubmed: 26071796
Front Oncol. 2021 Dec 24;11:771045
pubmed: 35004289
Lancet. 2023 Jul 24;:
pubmed: 37499670
Lancet. 2009 Feb 28;373(9665):746-58
pubmed: 19185342
Crit Rev Oncol Hematol. 2018 May;125:69-77
pubmed: 29650279